Sunyoung S. Lee, M.D., Ph.D.

Peer-Reviewed Articles

1. Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol:JCO2400081. e-Pub 2024. PMID: 39102622.
2. Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. e-Pub 2024. PMID: 39269823.
3. Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI. Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
4. Yim SY, Lee S, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee S, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS. Genomic Biomarkers to Predict Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma: Insights from the IMbrave150 Trial. Clin Mol Hepatol. e-Pub 2024. PMID: 39038962.
5. Tran Cao HS, Witt RG, Elsayes KM, Baiomy AA, Xiao L, Palmquist S, Lee SS, Mohamed YI, Mahvash A, Tzeng CD, Chun YS, Koay EJ, Rashid A, Hassan MM, Yao JC, Vauthey JN, Kaseb AO. Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features. Oncologist 29(6):e803-e810, 2024. e-Pub 2023. PMID: 38159256.
6. Oh DY, Ikeda M, Lee CK, Rojas C, Hsu CH, Kim JW, Shen L, Furuse J, Park JO, Borad M, de Braud F, Bridgewater J, Lee SS, Moehler M, Audhuy F, Osada M, Sato M, Yoo C. Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial. Hepatology. e-Pub 2024. PMID: 38875119.
7. Shi C, De B, Tran Cao HS, Liu S, Florez MA, Kouzy R, Grippin AJ, Katz MHG, Tzeng CD, Ikoma N, Kim MP, Lee S, Willis J, Noticewala SS, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Ludmir EB, Koay EJ. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med 13(12):e7434, 2024. PMID: 38923407.
8. Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I Trial of SPECT-Guided Liver-Directed Radiotherapy for Patients with Low Functional Liver Volume. JNCI Cancer Spectr 8(3), 2024. e-Pub 2024. PMID: 38730548.
9. Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol 8:e2300544, 2024. PMID: 38547421.
10. Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Cao HST, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. ASO Visual Abstract: Revisiting the Malignant Masquerade at the Liver Hilum-Have We Made Progress?. Ann Surg Oncol. e-Pub 2024. PMID: 38383662.
11. Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Tran Cao HS, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?. Ann Surg Oncol. e-Pub 2024. PMID: 38282027.
12. Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 11:455-461, 2024. e-Pub 2024. PMID: 38463542.
13. Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol 30(12):7309-7318, 2023. e-Pub 2023. PMID: 37679537.
14. DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. e-Pub 2023. PMID: 37972659.
15. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun 14(1):7621, 2023. e-Pub 2023. PMID: 37993437.
16. Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835569.
17. Swords DS, Newhook TE, Tzeng CD, Massarweh NN, Chun YS, Lee S, Kaseb AO, Ghobrial M, Vauthey JN, Tran Cao HS. ASO Visual Abstract: Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma. Ann Surg Oncol. e-Pub 2023. PMID: 37782416.
18. Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg 27(9):1867-1875, 2023. e-Pub 2023. PMID: 37268830.
19. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist 28(8):714-721, 2023. PMID: 36952233.
20. De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer 12(3):198-208, 2023. e-Pub 2023. PMID: 37593365.
21. Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?. HPB (Oxford) 25(4):472-480, 2023. e-Pub 2023. PMID: 36781357.
22. Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist, 2023. e-Pub 2023. PMID: 36715178.
23. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology 101(11):730-737, 2023. e-Pub 2023. PMID: 37467732.
24. Ahmed Z, Lee SS, Victor DW, Kodali S. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 10:1911-1922, 2023. e-Pub 2023. PMID: 37915617.
25. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget, 2022.
26. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H.. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022.
27. Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS.. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist, 2022. PMID: 35972334.
28. De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 128(13):2529-2539, 2022. e-Pub 2022. PMID: 35417569.
29. Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454808.
30. Kaseb A, Hasanov E, Tran Cao H, Xiao L, Vauthey J-N, Lee S, et al.. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterology and Hepatology, 2022.
31. Lee S, Shroff R, Makawita S, Xiao L, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff R, Javle M. Phase II, Open-Labeled, Single Arm Study of Ramucirumab for Advanced, Pre-Treated Biliary Tract Cancer. Clinical Cancer Research, 2022.
32. Lee S, Jeong Y, Lee S, Sohn B, Choi GH, Kang CM, Lee WJ, Cheong JH, Jang H-J, Kaseb A, Robert L, Chun YH, Lee J-S.. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications, 2022.
33. De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee S, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ.. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med, 2021.
34. Kaseb A, Kappadath SC, Lee S, Raghav K, Mohamed YI, Xiao L, Morris JF, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff R, Yao YC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90 Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021.
35. Yavuz BG, Hasanov E, Lee S, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021.
36. Mohamed YI, Lee S, Xiao L, et al. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget, 2021.
37. Demir T, Lee S, Kaseb AO. Systemic therapy of liver cancer. Advanced Cancer Research, 2021.
38. Mahalingam D, Chelis L, Nizamuddin I, Lee S, Kakolyris S, Halff G, Washburn K, Attwood K, Fahad I, Grigorieva J, Asmellash S, Meyer K, Oliveira C, Roder H, Roder J, Iyer R. Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrome-try-Based Test. Cancer, 2021.
39. Augustyna A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowsk GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee S, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical and Translational Radiation Oncology, 2021.
40. De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. Journal of Hepatocellular Carcinoma 8:57-69, 2021.
41. Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estefan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R. A multicenter phase Ib/II study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. British Journal of Cancer, 2020.
42. Hanif A, Lee S, Gupta M, Chander A, Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood K, Qiu J, Yendamuri S, Iyer R. Exploring the role of survivin in neuroendocrine neoplasms. Oncotarget, 2020.
43. Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 8(1):e1524695, 2019. e-Pub 2018. PMID: 30546965.
44. Lee S, Loecher M, Iyer R. Immunomodulation in hepatocellular cancer. Journal of Gastrointestinal Oncology, 2018.
45. Lee S, Salehi I, Chary M, Schiano T, Mascarenhas JO. "Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Transfus Apher Sci 55(1):105-8, 2016. e-Pub 2016. PMID: 27102761.
46. Zaiem F, Alkhawam H, Lee S, Fabisevich M. Severe symptomatic babesiosis co-infection with Lyme disease. QJM, 2016.
47. Lee S*, Khankhanian P, Salama C, Brown M, Lieber J.. Human granulocytic anaplasmosis-induced pseudo-Pelger-Huët anomaly. International Journal of Hematology, 2015.
48. Lee S, Khankhanian P, Mascarenhas J. Corticosteroid-induced morphological changes in cells of the myeloid lineage. American Journal of Hematology, 2015.
49. Lee S. Lee S. Basophilic granules of eosinophils in myelodysplastic syndrome and hypereosinophilia have heterogeneously shattered electron dense cores. Bloodmed – British Society of Haematology, 2015.
50. Lee S, Khankhanian P, Mascarenhas J. Dysplastic changes of peripheral eosinophils in acute myeloid leukemia with myelodysplastic syndrome-related features. Blood, 2015.
51. Lee S, Khankhanian P, Schneier A, Shiano T, Liu S, Machado O. Corticosteroid-treated cholestatic drug-induced liver injury complicated by miliary tuberculosis with associated adrenal insufficiency. European Review for Medical and Pharmacological Sciences, 2015.
52. Bakhsh U, Lee S, Ahmad S, Takher J, Pareek A, Syed U, Seashore J, Szemraj E.. Should prostate cancer be considered as a differential diagnosis in patients with osteolytic bone lesions?. European Review for Medical and Pharmacological Sciences, 2015.
53. Lee S, Chary M, Salehi I, Bansal R. Immune-mediated adalimumab-induced thrombocytopenia for the treatment of ulcerative colitis. International Journal of Pharmacy and Pharmaceutical Sciences, 2015.
54. Lee S*, Yang Y*, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nano-scale actin filament dynamics of ovarian cancer cells. Journal of Physical Chemistry B, 2013.
55. Fernandez CA, Roy R*, Lee S*, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR: a novel cell surface receptor for TIMP-2, Loop 6 of TIMP-2 binds IGF-IR. Journal of Biological Chemistry, 2010.
56. Lee S, Zeiger A, Maloney JM, Kotecki M, Van Vliet KJ, Herman IM.. Pericyte actomyosin-mediated contraction at the cell-material interface can modulate the microvascular niche. Journal of Physics-Condensed Matter, 2010.
57. Hwang DK, Oakey J, Toner M, Arthur JA, Anseth KS, Lee S, Zeiger A, Van Vliet KJ, Doyle PS. Stop-flow lithography for the production of shape-evolving degradable microgel particles. Journal of the American Chemical Society, 2009.
58. Chen AA, Khetani SR, Lee S, Bhatia SN, Van Vliet KJ. Modulation of hepatocyte phenotype in vitro via chemomechanical tuning of polyelectrolyte multilayers. Biomaterials, 2009.
59. Walton EB, Lee S, Van Vliet KJ. Extending Bell's model: how force transducer stiffness alters measured unbinding forces and kinetics of molecular complexes. Biophysical Journal, 2008.
60. Lee S, Mandic J, Van Vliet KJ. Chemomechanical mapping of ligand-receptor binding kinetics on cells. Proceedings of the National Academy of Sciences of USA, 2007.

Abstracts

1. Jaime Haro Silerio, Daniel Aaron Fox, Deepak Bhamidipati, Eugene Koay, Ethan Bernard Ludmir, Hyunseon Christine Kang, Deyali Chatterjee, Hop Sanderson Cao Tran, Jean Nicolas Vauthey, Timothy Eric Newhook, Ching-Wei David Tzeng, Yun Shin Chun, Armeen Mahvash, Zeyad A Metwalli, Peiman Habibollahi, Veronica Cox, Ahmed Kaseb, Milind Javle, Lee SS. Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Journal of Clinical Oncology, 2024.
2. Daniel Aaron Fox, Jaime Haro Silerio, Deepak Bhamidipati, Eugene Jon Kay, Ethan Bernard Ludmir, Deyali Chatterjee, Shubham Pant, Ian Hu, Ching-Wei David Tseng, Yun Shin Chun, Hop Sanderson Tran Cao, Timothy Eric Newhook, Jean Nicholas Vauthey, Ashton Connor, Sudha Kodali, Maen Abdelrahim, Veronica Cox, Hyunseon Christine Kang, Milind Javle, Lee SS. Characterizing outcomes of ERBB2-amplified biliary tract cancer. Journal of Clinical Oncology, 2024.
3. Jaime Haro Silerio, Daniel Aaron Fox, Deepak Bhamidipati, Eugene Koay, Ethan Bernard Ludmir, Hyunseon Christine Kang, Deyali Chatterjee, Hop Sanderson Cao Tran, Jean Nicolas Vauthey, Timothy Eric Newhook, Ching-Wei David Tzeng, Yun Shin Chun, Armeen Mahvash, Zeyad A Metwalli, Peiman Habibollahi, Veronica Cox, Ahmed Kaseb, Milind Javle, Lee SS. Genomic Characterization and Outcomes of Patients with Primary Sclerosing Cholangitis-related Cholangiocarcinoma. ESMO Precision Oncology, 2023.
4. Lee SS, Duan F, Jindal S, Basu S, Yadav S, Allison J, Sharma P, Mohamed Y, Kaseb A.. Combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer. Journal of Clinical Oncology, 2023.
5. Cham BB, Lee SS. Clinical outcomes and genomic evolution of FGFR2 fusions/rearrangements in intrahepatic cholangiocarcinoma. Cancer Research 82(12), 2022.
6. Lee HS, Kim K, Kang G, Jung KH, Kaseb A, Lee SS. Quantitative analysis of spatial distribution of lymphocytes in hepatocellular carcinoma: A biomarker correlated with survival and gene expression in cancer immune system. Journal of Clinical Oncology, 2022.
7. Lee HS, Kim K, Kang G, Jung KH, Lee SS. Spatial distribution of immune cells as quantitative prognosis indicator in hepatocellular carcinoma. Cancer Research 82(12), 2022.
8. Lee S, Tran Cao HS, Tzeng CD, Metwalli Z, Koay E, Ludmir EB, Chun YS, Chun SG, Javle M. Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers. Journal of Clinical Oncology, 2021.
9. Park J, Kim K, Lee HS, Kang G, Jung KH, Kaseb AO, Lee S. Impact of cell density in lymphocyte-rich areas in the tumor microenvironment on prognosis and gene expression landscape in hepatocellular carcinoma. Journal of Clinical Oncology, 2021.
10. Yeongwon Kim, Kyungdoc Kim, Jeonghyuk Park, Hyunho Park, Kyu-Hwan Jung and Sunyoung S. Lee. Deep learning-based analysis of tissue segmentation in histopathology images of colorectal cancer. Cancer Research, 2020.
11. Lee S, Abugabal Y, Baird A, Dolan J, Furqan F, Kaseb A. Risk score and prognostication modeling based on mRNA expressivity in the tumor microenvironment of hepatocellular carcinoma. Journal of Clinical Oncology 38:no. 15_suppl, 2020.
12. Mohamed YI, Qayyum A, Hassan M, Xiao L, Duda DG, Hatia R, Lee S, Wolff RA, Morris J, Altameemi L, Yao JC, Amin HM, Kaseb A. Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy. Journal of Clinical Oncology, 2020.
13. Lee S, Abugabal Y, Qayyum A, Hassan M, Xiao L, Duda D, Hatia R, Wolff R, Morris J, Altameemi L, Yao J, Amin H, Kaseb A. The role of ALBI and IGF-CTP score in refining prognostication of HCC. Journal of Clinical Oncology, 2020.
14. Kaseb A, Tran Cao H, Mohamed YI, Qayyum A, Vence LM, Blando JM, Singh S, Lee S, Raghav K, Altameemi L, Rashid A, Vauthey J-N, Carter K, Tzeng C-W, Chun SH, Yao JC, Wolff RA, Allison JP, Sharma P. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. Journal of Clinical Oncology, 2020.
15. Lee SH, Lee S, Lee J-S. Molecular validation of the 8th edition AJCC cancer staging system in patients with resected pancreatic cancer: Proposal of integrative translational staging system. Journal of Clinical Oncology, 2020.
16. Mohamed YI, Qayyum A, Hassan M, Xiao L, Duda DG, Hatia R, Lee S, Wolff RA, Morris J, Altameemi L, Yao JC, Amin HM, Kaseb A. IGF-Child-Turcotte-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy. Journal of Clinical Oncology, 2020.
17. Abdou Y, Baird A, Dolan J, Lee S, Park S, Lee S. Prognostication model based on genomic expression in the tumor microenvironment of ER-positive, HER2-negative stage III breast cancer via machine learning. Journal of Clinical Oncology, 2020.
18. Abugabal Y, Qayyum A, Hassan M, Xiao L, Duda D, Hatia R, Lee S, Wolff R, Pestana R, Morris J, Yao J, Amin H, Kaseb A. IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 2020.
19. Abdou Y, Baird A, Dolan J, Lee S, Park S, and Lee S. Machine learning-assisted prognostication based on genomic expression in the tumour microenvironment of estrogen receptor positive and HER2 negative breast cancer. Annals of Oncology, 2019.
20. Lee S, Attwood, K, Roder H, Asmellash S, Meyer K, Kakolyris S, Oliveira C, Roder J, Grigorieva J, Chelis L, Iyer R, Mahalingam D. An independent validation of a screening test using mass spectrometry for detection of hepatocellular carcinoma. Cancer Research, 2019.
21. Lee S, Jerez J, Elkhanany A, Farrukh F, Baird A, Baird S, Dolan J. Risk score and prognosis modeling based on mRNA expressivity in the tumor microenvironment of GI cancers. Journal of Clinical Oncology, 2019.
22. Lee S, Kwon SJ, Lee DE, Lee S, Baird A, Park S, Dolan J, George S. Modeling of prognostication and differential genomic expression in the tumor microenvironment of clear cell renal cell carcinoma. Journal of Clinical Oncology, 2019.
23. Lee S, Kim JC, Lee S, Dolan J, and Baird A. Automated mapping and analysis of stromal cells in tumor microenvironment in pancreatic adenocarcinoma and cholangiocarcinoma using deep learning. Cancer Research, 2018.
24. Lee S, Kim JC, Dolan J, and Baird, A. Automation of quantifying and mapping of stromal and malignant cells in pancreatic adenocarcinoma using deep learning. Journal of Clinical Oncology, 2018.
25. Lee S, Salehi I, Chary M, Schiano T, Mascarenhas J. Irony of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. Pediatric Blood & Cancer, 2015.
26. Lee S, Schneier A, Petersen B, Gabrilove J, Lin J. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma, mimicking Chinese herb-induced liver failure. Pediatric Blood & Cancer, 2015.
27. Lee S, Schneier A, Petersen B, Gabrilove J, Lin J. Fulminant hepatic failure from hemophagocytic lymphohistiocytosis secondary to hepatosplenic T-cell lymphoma, mimicking Chinese herb-induced liver failure. Journal of Investigative Medicine, 2015.
28. Lee S, Chary M, Mascarenhas J. Paraneoplastic orthostatic hypotension associated with acute myeloid leukemia with trisomy 8. Journal of Investigative Medicine, 2015.
29. Lee S, Khankhanian P, Salama C, Brown M, Lieber J. Pseudo-Pelger-Huët anomaly and granulcytic dysplasia associated with human granulocytic anaplasmosis. Journal of Investigative Medicine, 2015.
30. Lee S, Chary M, Fadi S, Petersen B, Lin J. Evolution of peripheral blood smear and lymph node histology in miliary tuberculosis. Journal of Investigative Medicine, 2015.
31. Lee S, Khankhanian P, Schneier A, Shiano T, Liu S, Machado O. Cholestatic drug-induced liver injury treated with corticosteroid in a patient with miliary tuberculosis and associated adrenal insufficiency. Journal of Investigative Medicine, 2015.
32. Lee S, Khankhanian P, Mascarenhas J. Corticosteroid-induced morphological changes in cells of the myeloid lineage. Journal of Investigative Medicine, 2015.
33. Lee S, Chary M, Mascarenhas J. Irony of transfusional support for refractory anemia in hemophagocytic lymphohistiocytosis. Journal of Investigative Medicine, 2015.

Book Chapters

1. Lee S, Zhang HC, Tran Cao HS, Kodali S, Kuban JD, Koay EJ, Avritscher R, Kaseb AO. Hepatocellular Carcinoma. In: The MD Anderson Manual of Medical Oncology, 4th edition. McGraw-Hill Education, 2021.
2. Makawita S, Lee S, Chun YS, Roach MA, Koay EJ, Javle M.. Biliary Tract Cancer. In: The MD Anderson Manual of Medical Oncology, 4th edition. McGraw-Hill Education, 2021.
3. Demir T, Lee S, Kaseb AO. Systemic therapy of liver cancer, Mechanisms and Therapy of Liver Cancer. In: Advances in Cancer Research. Elsevier, 2021.
4. Lee S, Dy G. Immune checkpoint inhibitors in lung cancer. In: Immune Checkpoint Inhibitors in Cancer, 2018.
5. Lee S, Loecher M, Puzanov I. Toxicities in immune checkpoint inhibitors. In: Immune Checkpoint Inhibitors in Cancer, 2018.
6. Fountzilas C, Lee S, Iyer R, Boland P. Immune checkpoint inhibitors in gastrointestinal malignancies. In: Immune Checkpoint Inhibitors in Cancer, 2018.